Redeye leaves a comment following Alzinova’s announced study data form the high-dose phase Ib extens...
Sales +0%, EBIT +31% vs. ABGSCe, beat driven by FX revaluations Underlying EBIT in line with our exp...
Raketech’s Q4-results were in line with the preannouncement from February 4 where the company report...
Marimekko's fourth quarter revenue beat our estimates slightly due to strong development in Finland.
Redeye provides its initial take on Surgical Science’s Q4 2024 report, which featured decent top lin...
Vaisala’s 2024 ended on a strong note as was expected after January’s positive profit warning.
Redeye comments on Medivir's Q4 report of 2024. In the quarter, the phase IIa study of fostrox was c...
Redeye concludes that Smart Eye's Q4 2024 report was even better than it looked at first sight.
Redeye updates on Gentoo Media post Q4-results where we see continued growth potential in the coming...
Redeye comments on the evening’s news regarding Integrum’s strategic shift for accelerating OPRA com...
24% organic sales growth y-o-y Improved gross margin due to pricing and mix Opex flat y-o-y leads to...
Redeye gives a short comment on today’s news that IRLAB extends its runway following “extended and e...
Redeye notes that the underlying Q4 figures came in stronger than anticipated, primarily due to bett...
Vaisala's Q4 results aligned with the preliminary figures the company disclosed in January.
Strong organic growth in Q4 at 18%, albeit 2% below ABGSCe Q4 adj.
